ACM
VIRX

Aisling Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Aisling Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-288,571
Closed -$46.2K – 14
2024
Q4 		$46.2K Hold
288,571
– – 0.02% 15
2024
Q3 		$66.4K Hold
288,571
– – 0.03% 16
2024
Q2 		$157K Hold
288,571
– – 0.07% 15
2024
Q1 		$294K Hold
288,571
– – 0.1% 16
2023
Q4 		$164K Hold
288,571
– – 0.05% 15
2023
Q3 		$300K Hold
288,571
– – 0.12% 16
2023
Q2 		$407K Hold
288,571
– – 0.2% 15
2023
Q1 		$459K Hold
288,571
– – 0.22% 14
2022
Q4 		$421K Hold
288,571
– – 0.28% 15
2022
Q3 		$1.23M Hold
288,571
– – 0.82% 12
2022
Q2 		$1.12M Hold
288,571
– – 0.8% 13
2022
Q1 		$1.37M Hold
288,571
– – 0.74% 16
2021
Q4 		$1.05M Hold
288,571
– – 0.37% 20
2021
Q3 		$2.31M Hold
288,571
– – 0.46% 19
2021
Q2 		$3.27M Buy
+288,571
New +$2.9M 0.52% 19
2021
Q1 		– Sell
-288,571
Closed -$2.01M – 16
2020
Q4 		$2.01M Hold
288,571
– – 0.35% 14
2020
Q3 		$1.26M Hold
288,571
– – 0.4% 14
2020
Q2 		$2.66M Hold
288,571
– – 1.02% 9
2020
Q1 		$4.19M Hold
288,571
– – 1.83% 8
2019
Q4 		$3.41M Hold
288,571
– – 1.31% 9
2019
Q3 		$7.27M Buy
288,571
+71,428
+33% +$2.06M 3.79% 7
2019
Q2 		$5.55M Hold
217,143
– – 2.37% 10
2019
Q1 		$9.23M Buy
217,143
+142,857
+192% +$3.24M 7.03% 7
2018
Q4 		$1.09M Buy
+74,286
New +$3.03M 1.15% 12

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Aisling Capital Management's VIRX Position: Q1 2025 in Review

Aisling Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 288,571 shares — an estimated $46.2K sold.

Aisling Capital Management first reported a position in VIRX in Q4 2018 and held it in 24 quarters. The position peaked at $9.23M in Q1 2019. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Aisling Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Aisling Capital Management sold 288,571 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $46.2K.
  • Aisling Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 24 quarters.
  • Aisling Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $9.23M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Aisling Capital Management's 13F filing for Q1 2025, filed 13 May 2025.